Clinical Trials Logo

Clinical Trial Summary

It is a single-arm, open-label, multicenter, phase II study to evaluate the safety, efficacy, pharmacokinetics (PK) and immunogenicity of AK104 as a single agent in subjects with previously-treated locally advanced unresectable or metastatic MSI-H or dMMR solid tumors.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04547101
Study type Interventional
Source Akeso
Status Terminated
Phase Phase 2
Start date April 24, 2020
Completion date September 30, 2022